Welcome to our dedicated page for Cellectis news (Ticker: CLLS), a resource for investors and traders seeking the latest updates and insights on Cellectis stock.
Cellectis S.A. develops gene-edited cell and gene therapies as a clinical-stage biotechnology company. Its recurring news centers on allogeneic CAR T immunotherapies in oncology, including off-the-shelf, gene-edited CAR T-cell product candidates, and on broader gene therapy research using its gene-editing platform and in-house manufacturing capabilities.
Company updates commonly cover clinical and partner-program developments for candidates such as lasme-cel, eti-cel and cema-cel; TALE-based and epigenetic editing research; financial results and business updates; collaborations and license arrangements; and monthly disclosures of share capital and voting rights for its Euronext Growth listing alongside its Nasdaq-listed ADS trading under CLLS.
Cellectis (Euronext Growth: CLLS) reports monthly share capital and voting rights as of January 31, 2026. The company lists 100,590,994 total shares and 105,825,481 total voting rights. ISIN: FR0010425595. Contact details provided for media and investors.
Cellectis (NASDAQ:CLLS) outlined its 2026 strategy focused on advancing allogeneic CAR-T candidates and delivering multiple clinical catalysts. Key near-term milestones include a pivotal Phase 2 BALLI-01 interim analysis for lasme-cel (n=40) expected in Q4 2026, presentation of the full Phase 1 NATHALI-01 dataset for eti-cel in r/r NHL in Q4 2026, and a Q1 2026 IL-2 enrollment cohort for NATHALI-01. Phase 1 highlights for lasme-cel: ORR 68% (Process 2), 83% at RP2D, 100% in the target Phase 2 population, 56% CR/CRi with ~80% MRD-negativity, and 14.8 months median OS in MRD-neg CR/CRi. The company expects cash to fund operations into H2 2027 and continues collaborations with AstraZeneca, Servier/Allogene and Iovance.
Cellectis (Euronext Growth: CLLS) published its monthly information on share capital and voting rights as of December 31, 2025. The release lists the total number of shares and total voting rights recorded on that date.
- ISIN: FR0010425595
- Date: 12/31/2025
- Total shares: 100,339,441
- Total voting rights: 105,576,356
Contact details for media and investor relations were provided for further information.
Cellectis (NASDAQ: CLLS) announced an Arbitral Tribunal decision dated December 15, 2025 in its arbitration with Les Laboratoires Servier and IRIS SARL relating to the March 6, 2019 License Agreement.
The Tribunal ordered a partial termination of the License Agreement with respect to product UCART19 V1 (also called ALLO-501) and provided that Cellectis shall, at Allogene’s request, engage in good-faith discussions about granting a direct license to UCART19 V1. All other claims between the parties were dismissed.
Cellectis (NASDAQ:CLLS) presented updated Phase 1 NATHALI-01 data for eti-cel, an allogeneic dual CD20/CD22 CAR-T for relapsed/refractory non-Hodgkin lymphoma (r/r NHL).
At the current dose level, eti-cel showed an 88% overall response rate (ORR) and 63% complete response (CR) in n=8 patients. In vivo data suggested that low-dose interleukin-2 (IL-2) support may enhance CAR-T expansion and persistence without increasing toxicity. Cellectis will begin enrollment in an IL-2 support cohort in Q1 2026 and expects to present the full Phase 1 dataset in 2026. The poster will be posted on the company website.
Cellectis (CLLS) published its monthly information on share capital and voting rights as of November 30, 2025. The release reports the total number of shares as 100,325,454 and the total number of voting rights as 105,406,812. The announcement lists the listing market as Euronext Growth and the ISIN code as FR0010425595. Contact details for media and investor relations are provided for further information.
Cellectis (NASDAQ: CLLS) published a Nature Communications article on Nov 19, 2025 describing a non-viral gene insertion process using circular single-stranded DNA (CssDNA) donor templates combined with TALEN gene editing in hematopoietic stem and progenitor cells (HSPCs).
Key results: CssDNA produced 3–5x higher knock-in efficiency than linear ssDNA with efficiencies surpassing 40%; CssDNA enabled insertion at multiple HSPC loci and worked in primary T cells; CssDNA-edited HSPCs showed higher engraftment and maintenance of edits in a murine model versus AAV6-edited HSPCs.
This work positions CssDNA as an efficient non-viral strategy to expand durable gene and cell therapy options.
Cellectis (NASDAQ: CLLS) reported Q3 2025 results and a business update on Nov 7, 2025. Key clinical highlights: lasme-cel (UCART22) Phase 1 P2 ORR 68% (n=22), RP2D ORR 83% (n=12) and 100% in target Phase 2 population (n=9); median OS 14.8 months in MRD-negative CR/CRi patients. eti-cel (UCART20x22) preliminary ORR 86% and CR 57% (n=7); full Phase 1 dataset expected in 2026 and an ASH 2025 poster on Dec 7.
Finance: consolidated cash, cash equivalents and fixed-term deposits of $225M as of Sept 30, 2025 (runway into H2 2027); nine-month revenue $67.4M (vs $34.1M prior year); consolidated net loss attributable to shareholders $41.3M for nine months. Servier arbitration decision expected on or before Dec 15, 2025.
Cellectis (Euronext Growth: CLLS) published its monthly report on share capital and voting rights as of Oct 31, 2025.
Key figures: Total number of shares = 100,325,454; Total number of voting rights = 89,406,760. The disclosure follows Article 223-16 of the French financial markets authority general regulation and lists investor and media contact details for further information.
Cellectis (NASDAQ: CLLS) announced two accepted posters for ASH 2025 (Dec 6–9, 2025) in Orlando reporting clinical updates on allogeneic CAR-T programs eti-cel (UCART20x22) and lasme-cel (UCART22).
Preliminary eti-cel Phase 1 results show an 86% ORR and 57% CR at the current dose (n=7); Cellectis plans to present the full Phase 1 dataset, including low-dose IL-2 combination cohorts, in 2026. A preclinical signal suggests low-dose IL-2 may deepen and extend anti-tumor activity.
The lasme-cel poster reports a correlation between alemtuzumab exposure and depth of response in BALLI-01, identifying a threshold exposure linked to higher CR/CRi rates without increased toxicities and supporting planned pivotal Phase 2 enrollment in Q4 2025.